BDRX
BDRX clinical trials: Biodexa Pharmaceuticals Plc
Every trial on ClinicalTrials.gov where Biodexa Pharmaceuticals Plc is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 4
- Trials linked
- 2
- As lead sponsor
- 2
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
BDRX on the catalyst calendar · BDRX registry changes
- Primary completion Not registeredNo phase registeredNCT07689942Expanded Access to 0.5 mg eRapa for Familial Adenomatous PolyposisBiodexa Pharmaceuticals · Familial Adenomatous Polyposis (FAP)AvailableBDRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 10, 2024ActualPhase 1NCT05324501A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent GlioblastomaBiodexa Pharmaceuticals · Recurrent GlioblastomaTerminatedBDRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 11, 2024ActualPhase 2NCT04230499Trial of eRapa to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active SurveillanceRapamycin Holdings Inc. · Familial Adenomatous PolyposisCompletedBDRXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2030Sponsor estimatePhase 3NCT06950385Phase 3 Trial of eRapa in Patients With Familial Adenomatous PolyposisRapamycin Holdings Inc. · Familial Adenomatous Polyposis (FAP)RecruitingBDRXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 4 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner